Thus, clinical trials on inhibitors of the EZH2 enzyme are currently underway in tumors with complete loss of SMARCB1/INI1 expression, including poorly differentiated chordomas (ClinicalTrials.gov Identifiers: NCT02601950 and NCT05407441) [30,31,32]. Here, SMARCB1 is linked to chordoma.